Daily Program

NB: Timing and speaker order within tracks to be determined.

14 May 2019

+
09:30  -  11:20
Hall A

Opening Session

09:30-10:00 Welcome by Conference Chairpersons:
Ruti Alon, Founder and CEO, Medstrada
Ora Dra, PhD, Israel Innovation Authority
Nissim Darvish, MD, PhD, Senior Managing Director, Orbimed

10:00-10:40 Robert C. King, PhD, Partner at Goldman Sachs International and Global Vice Chairman, Investment Banking Division

10:40-11:20 Barry Greene, President, Alnylam Pharmaceuticals: “Nobel Prize-Winning Science to First Approved RNAi therapeutic”

+
11:20  -  11:50

Coffee Break

+
11:50
Hall A

Gene Editing and Gene Therapy: The Next Frontier in Human Health

Co-chairs: Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx; Stephen Squinto, PhD, Interim CEO, Passage Bio

11:50-12:00 Opening by Co-chairs

12:00-12:20 Adi Barzel, PhD, Senior Lecturer, Department of Biochemistry at Tel Aviv University; Co-Founder of LogicBio Therapeutics, Inc.; President of the Israeli Society of Gene and Cell Therapy: “Principles of Gene Editing; CRISPR in B Cells Fighting AIDS”

12:20-12:40 Ulrich Brinkmann, PhD, Scientific Director, Roche Pharma Research & Early Development, Roche Diagnostics GmbH: “Nucleic Acid Therapeutics Including Delivery and CRISPR”

12:40-13:00 Prof. Nadav Ahituv, PhD, Department of Bioengineering and Therapeutic Science, University of California San Francisco: “CRISPRa Therapeutics for Haploinsufficient Disease”

13:00-13:20 Rachel Haurwitz, PhD, Co-founder, President and CEO, Caribou Biosciences

13:20-13:35 Company TBC

13:35-13:50 Company TBC

13:50-15:20 Lunch Break

15:20-15:45 Ronald G. Crystal, MD, Chair, Department of Genetic Medicine, Weill Cornell Medical College

15:45-16:05 Stephen Squinto, PhD, Interim CEO, Passage Bio

16:05-16:25 Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx; “Using Gene Therapy for the Treatment of Rare Genetic Liver Disease”

16:25-16:40 Trevor Martin, PhD, CEO and Co-Founder, Mammoth Biosciences: “The Next Generation of CRISPR Tools”

16:40-16:55 Dalia El-Ani, PhD, Chief Executive Officer, Crispr Stem & Therapeutics: “CRISPR: A Novel Gene Therapy to Protect the Heart from Acute Ischemic Damage”

16:55-17:40 “Panel Discussion
Panelists:
Ronald G. Crystal, MD, Chair, Department of Genetic Medicine, Weill Cornell Medical College
Rachel Haurwitz, PhD, Co-founder, President and CEO, Caribou Biosciences
Prof. Nadav Ahituv, PhD, Department of Bioengineering and Therapeutic Science, University of California San Francisco
Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx
Stephen Squinto, PhD, Interim CEO, Passage Bio

+
11:50  -  17:10
Hall B

Transforming Medicine: Artificial Intelligence and Digital Health

Co-chairs: Anat Naschitz, Managing Director, OrbiMed Advisors; Allen Kamer, Managing Partner, OurCrowd Qure

11:50-11:55 Opening by Co-chairs

11:55-12:20 Don Mathis, General Manager, Growth, Comcast NBCUniversal

12:20-12:45 Elliot Menschik, MD, PhD, Global Head Healthcare and Lifescience Startups, Amazon: “Democratizing AI/ML Capabilities and Accelerating their Impact on Healthcare”

12:45-13:00 Doron Behar, MD, PhD, CEO, Igentify: “An End-to-end & Scalable Digital Platform Designed for Web-assisted Genetic Counselling”

13:00-13:15 Yaron Gurovich, CTO, FDNA: “Facial Features + Genomics = Diagnosis”

13:15-13:30 Itay Bengad, CEO, MDGO: “Your Car Knows your Injuries”

13:30-13:50 Fireside Chat – Working Together to Liberate Data. A Hospital Perspective
Moderator: Anat Naschitz, Managing Director, OrbiMed Advisors.
Michael Phillips, MD, MBA, Partner and Managing Director, Intermountain Ventures
Ziv Ofek, Founder and CEO, MDClone

13:50-15:20 Lunch Break

15:20-15:40 Avinatan Hassidim, Head of TLV Research, Google: “How Google uses Machine Learning for Medical Research”

15:40-15:55 Hadas Bitran, Head of Healthcare Israel, Microsoft: “Microsoft – Healthcare Innovation”

15:55-16:10 Tamara Mansfeld, Global Innovation Lead, Pfizer: “AI in Drug Discovery”

16:10-16:25 David Harel, Founder and CEO, CytoReason: “Machine Learning for Drug Discovery and Development”

16:25-16:40 Leif E. Pedersen, CEO, Dassault Systemes BIOVIA

16:40-16:55 Avi Veidman, Founder and CEO, Nucleai: “Harnessing AI for Pathology”

16:55-17:10 Ariel Beery, Founder and CEO, MobileODT: “Using Augmented Reality at the Point of Care to Eliminate Cervical Cancer”

+
11:50  -  17:25
Hall C

Disruptive and Advanced Medical Devices

Co-chairs: Irit Yaniv, MD, General Partner, Accelmed; Ron Ginor, MD, Venture Partner, OrbiMed Advisors, L.L.C

11:50-11:55 Opening by Co-chairs

11:55-12:10 Bruce R. Rosengard, MD, VP, Global External Innovation, Johnson and Johnson Medical Devices: “Market Perspective”

12:10-12:25 Oren Goldshtein, Vectorius Medical Technologies: “Transforming Heart Failure Treatment with the World’s First In-heart Microcomputer”

12:25-12:40 Ofri Vaisman, COO, Bluewind Medical: “Bluewind Medical Renova System – Neurostimulation Therapy for Over Active Bladder”

12:40-12:55 Ron Aginsky, President, FUS Mobile: “Non-Invasive Procedure for Interventional Pain Managment Treatment”

13:00-13:15 Nicholas Pachuda, WW Vice President, Orthopedic Innovation, J&J Medical Devices: “Field Specific – Orthopedics”

13:15-13:30 Yehiel Tal, CEO, Collplant Ltd, “rhCollagen – the Ideal Building Block for Regenerative Medicine”

13:30-13:45 Company TBC

13:50-15:20 Lunch Break

15:20-15:35 John J. Smith, MD, Partner, Hogan Lovells: “Regulatory Perspective”

15:35-15:50 Nitai Hanani, CEO, Paragate Medical: “Implantable Peritoneal Ultrafiltration Device for Fluid Overload Treatment”

15:50-16:05 David Israeli, CEO, Magenta Medical: “Minimally-Invasive Blood Pumps for the Treatment of Acute Heart Failure”

16:05-16:20 Prof. Joel V. Brill, MD, FACP, Chief Medical Officer, Predictive Health. LLC: “Reimbursement Perspective”

16:20-16:35 Yoram Solberg, Brainsgate: “Spheno Palatine Ganglion Stimulation for Treatment of Acute Ischemic Stroke”

16:35-16:50 Company TBC

16:50-17:05 Shai Policker, Medxelerator, “Incubator Perspective”

17:05-17:20 Eric Tansky, Managing Director, Oppenheimer & Co. Inc.: “Funding Perspective”

17:20-17:25 Closing by Co-chairs

15 May 2019

+
09:30  -  11:40
Hall A

Plenary Session

09:30-09:50 Amy W. Schulman, Managing Partner, LS Polaris Innovation Fund and Polaris Partners: “Platform Startups – The Boston Biotech Ecosystem and Beyond”

09:50-10:10 Aharon Aharon, CEO, Israel Innovation Authority: “Bio-convergence – the Future of Israeli Healthtech”

10:10-11:00 Corporate Panel:
Moderator: Francois Maisonrouge, Senior Managing Director, Evercore Partners
Panelists:
Fiona de Hemptinne, Venture Partner, UCB Ventures
Miriam Frieden, PhD, MBA, VP of Search and Evaluation, Novo Nordisk
Laurent Choppe, DVM, Managing Partner, Cukierman & Co. Life Sciences
Zafrira Avnur, PhD, CSO & Partner, VP Quark Venture Inc.
Tina Xu, Vice President of Information Technology and Head of Business Innovation, AstraZeneca China
Max Zeiberg, Corporate Development, Gilead Sciences

11:00-11:40 Todd Brinton, MD, Corporate Vice President, Advanced Technology and Chief Scientific Officer, Edwards Lifesciences

 

+
11:40  -  12:10

Coffee Break

+
12:10  -  17:15
Hall A

Prevention and Rehabilitation: Should the Underdog Begin Barking?

Chair: Naomi Gefen, Deputy Director General, ALYN Hospital

Opening Session

12:10-12:25 Maurit Beerim MD, Director General, ALYN Hospital: “From Prevention to Rehabilitation”

12:25-12:45 Yoav Medan, PhD: “Using Technology to Advance Prevention and Rehabilitation“

Circle of Life: Prevention and Rehab for all ages

12:45-13:05 Sagit Arbel-Alon, MD, Deputy Director, Reuth Medical & Rehabilitation Hospital: “Geriatric Rehabilitation”

13:05-13:20 Company TBC

13:20-13:35 Or Retzkin, CEO & Co-founder; EyeControl: “EyeControl: Inspiring Communication”

13:35-13:55 Itamar Offer, MD,MPA, CEO, Sabar Health: “Rehabilitation at Home”

13:55-14:10 Yotam Drechsler, CEO, BrainQ technologies: “BCI Based Stimulation Device- BQ (BrainQ technologies)”

14:10-15:40 Lunch Break

15:40-15:55 Maurit Beeri, MD, Director General, ALYN Hospital: “Pediatric Rehabilitation”

15:55-16:10 Yotam Bahat, CEO, Senserum: “SENSERUM – VR for Clinical Use”

Taking Rehab to Another Level – Enabling Meaningful Participation in the Community and Workplace

16:10-16:25 Daniel Barel, CEO, SoftWheel: “SoftWheel – Innovative Technology for Mobility Solutions”

16:25-16:55 Yaron Galitzky, General Manager, Devices & Accessories, Microsoft; “Xbox Adaptive Controller”

16:55-17:15 Ziv Shilon, Co-founder, COO, 6Degrees: “Be the Hero of your Own Story”

+
12:10  -  17:25
Hall B

Tango of the Two: Academia and Industry

Co-chairs: Prof. Yael Hanein, PhD, School of Electrical Engineering, Tel Aviv University; Yaron Daniely, PhD, CEO, Yissum

12:10-12:40 Speaker TBC

12:40-12:55 Prof. Yaakov Nahmais, PhD, Director, Grass Center for Bioengineering, The Hebrew University of Jerusalem

12:55-13:10 Company TBC

13:10-13:25 Prof. Yael Hanein, PhD, School of Electrical Engineering, Tel Aviv University: “Monitoring Sleep Stages at Home”

13:25-14:10 Panel discussion: Lessons Learnt by Researchers
Moderator: Prof. Yael Hanein, PhD, School of Electrical Engineering, Tel Aviv University
Panelists
Prof. David Mirelman, PhD, Weizmann Institute of Science
Prof. Gal Markel, MD, PhD, Tel Aviv University
Prof. Daniel Offen, PhD, Tel Aviv University

14:10-15:40 Lunch Break

15:40-15:55 Tal Dvir, Tel Aviv University: “Printed Heart”

15:55-16:10 Company TBC

16:10-16:25 Eran Stark, MD, PhD, Sackler Faculty of MedicineTel Aviv University: “Penetrating Neural Probes”

16:25-16:40 Company TBC

16:40-16:55 Company TBC

16:55-17:10 Uzi Sopher, Alpha TAU Medical: “First Alpha-radiation Cancer Treatment for Solid Tumors”

17:10-17:41 TBC

17:410-17:56 Panel Discussion: It Takes a Village: Boosting the Volume and Quality of Academic Entrepreneurship
Moderator: Yaron Daniely, PhD, CEO, Yissum
Panelists:
Aviv Zeevi, PhD, VP, Technology Infrastructure Division
Kelly Krajnik, Senior Manager, Devices, Diagnostics, Mayo Clinic Ventures

+
12:10  -  17:40
Hall C

New Modalities of Cell Therapies: Revolutionizing the Way We Treat Diseases

Co-chairs: Aya Jakobovits, PhD, Founder, Director, Adicet Bio; Erez Chimovits, Senior Managing Director, OrbiMed Advisors

12:10-12:15 Opening remarks by Co-chairs

12:15-12:40 Aya Jakobovits, PhD, Founder, Director, Adicet Bio: “Adoptive Cell Therapy 3.0”

12:40-13:05 Carl L. Gordon, PhD, Managing Partner, OrbiMed Advisors: “The Cell Therapy Field has already Generated some of the Best Returns in Biotechnology, and the Best is Yet to Come, Based on Enhanced Cell Therapy Technologies”

13:05-13:20 Prof. Angel Progador, PhD, Ben-Gurion University: “NK Cells”

13:20-13:35 Prof. Ofer Mandelboim, PhD, Hebrew University of Jeruaslem: “Tumor Microenvironment and Bacteria”

13:35-13:50 Michal J. Besser, PhD, Head of Laboratory, Ella Lemelbaum Institute for Immuno Oncology & Director, Wohl GMP Facility, Sheba Medical Center; Assistant Professor, Dept. of Microbiology and Immunology, School of Medicine, Tel Aviv University: “Clinical Experience with In-house Produced CAR T Cells”

13:50-14:05 Stewart Abbot, PhD, Chief Operating Officer, Adicet: “Off-the-shelf, Engineered Gamma Delta T-cell Therapies”

14:05-14:10 Aya Jakobovits, PhD, Founder, Director, Adicet Bio: “Session #1 Summary”

14:10-15:40 Lunch Break

15:40-15:55 Merav Beiman, PhD, CEO, ImmPACT-Bio: “Next Generation CAR-T Engineering Solving the ‘On-Target’ ‘Off-Tumor’ Issue towards Broader, Safer and Effective CAR-T Therapies”

15:55-16:10 Amy W. Schulman, Executive Chair, SQZ Therapeutics: “SQZ Biotech: Unleashing the Power of Cells”

16:10-16:25 Yoav Ben Ya’acov, CEO, CTG Pharma: “CTG Pharma- Safe CAR T Therapy for Solid Tumors”

16:25-16:40 Julian Adams, PhD, Chief Executive Officer, Gamida Cell: “Ex- vivo Expansion of Natural Killer (NK) Cells to Treat B-Cell Lymphoma and Multiple Myeloma”

16:40-16:55 Shmulik Hess, CEO, Enlivex Therapeutics R&D LTD: “Enilvex Therapeutics, Immune Rebalancing”

16:55-17:40 Panel Discussion: “The Path for Effective and Accessible Cancer Cell Therapy” 

16 May 2019

+
09:30  -  10:50
Hall A

Plenary Session

09:30-10:10 Tom Sudow, Director, Business Development, Cleveland Clinic Innovations; Mark D. Stovsky, MD, MBA, FACS, Senior Director, Emerging Business, Cleveland Clinic Ventures

10:10-10:50 Jeroen Tas, Chief Innovation & Strategy Officer, Philips

+
10:50  -  11:20

Coffee Break

+
11:20  -  17:30
Hall A

Transformative Cancer Therapies

Chair: Prof. David Sidransky, MD, Johns Hopkins School of Medicine; Co-Founder and General Partner, Israel Biotech Fund

11:20-11:25 Opening by Chair

11:25-11:50 Gary Gordon, MD, PhD, Former Vice President, Global Oncology Development, AbbVie, Inc: “The 20 Year Journey of an Oncology Drug”

11:50-12:05 Kandeepan Ganeshalingam, MD, Executive Director Therapeutic Area Head Oncology – EU Clinical Development, Merck Sharp & Dohme: “MSD Immune-oncology Innovative Therapies”

12:05-12:20 Ruth Ben Yakar, PhD, Chief Executive Officer, BioSight: “Biosight Ltd. is Developing BST-236, a Novel Antimetabolite for First-line Treatment of Hematological Malignancies and Disorders”

12:20-12:35 Julian Adams, PhD, Chief Executive Officer, Gamida Cell: “Ex Vivo Expanded Cells to Treat Hematological Malignancies”

12:35-12:50 Baruch Schori, Chief Executive Officer, PTM Biosciences: “PTM Biosciences is Promoting Precision Medicine by Transforming Post-Translational Modifications into Novel Therapeutic Targets and Biomarkers for Disease Management”

12:50-13:05 Tehila Ben Moshe, PhD, Chief Executive Officer & Co-Founder, Biond Biologics: “Biond Biologics: From Innovative Science to the Clinic; Transforming the Treatment of Cancer”

13:05-13:20 Hadas Reuveni, PhD, Chief Executive Officer, TyrNovo LTD: “NT-219, a First-in-class Dual Inhibitor of STAT3 and IRS1/2 is Overcoming Drug Resistance”

13:20-14:50 Lunch Break

14:50-15:10 Ulrich Brinkmann, PhD, Scientific Director, Roche Pharma Research & Early Development, Roche Diagnostics GmbH: “Bi-Specific Antibodies and Fusion Proteins in Cancer Therapy”

15:10-15:25 Prof. Dror Harats, CEO Vascular Biogenics: “Turning ‘Cold’ Tumor into ‘Hot’ Tumor – Lessons from  VB-111, a Viral Immuno-oncology Agent and VB-611, a Novel Bi-specific Antibody”

15:25-15:40 Roni Mamluk, PhD, Chief Executive Officer, Ayala: “Ayala Pharmaceuticals – Precision Oncology Targeted Therapy”

15:40-15:55 Frank Haluska, MD, PhD, Chief Executive Ofiicer, Anchiano Therapeutics: “Gene Therapy for Early Stage Bladder Cancer: The Pivotal Program with Inodiftagene”

15:55-16:10 Asher Nathan, CEO, NeoTX Therapeutics Ltd: “Selective T Cell Redirection (STR): A Second Generation Immunotherapy”

16:10-16:40 Amnon Peled, PhD, Chief Executive Officer, Biokine Therapeutics: “Development of First in Class High Affinity Small Molecule Antagonist of a Novel Cancer Target Critical for Tumor Cell Migration and Survival”

16:40-17:30 Panel Discussion: Combination Therapy: How to Minimize Development Costs and Maximize Efficiency to Market
Moderator: Prof. David Sidransky, MD, Johns Hopkins School of Medicine; Co-Founder and General Partner, Israel Biotech Fund
Kandeepan Ganeshalingam, MD, Executive Director Therapeutic Area Head Oncology – EU Clinical Development, Merck Sharp & Dohme
Gary Gordon, MD, PhD, Former Vice President, Global Oncology Development, AbbVie, Inc
Frank Haluska, PhD, Chief Executive Ofiicer, Anchiano Therapeutics
Julian Adams, PhD, Chief Executive Officer, Gamida Cell
Ulrich Brinkmann, PhD, Scientific Director, Roche Pharma Research & Early Development, Roche Diagnostics GmbH”

+
11:20  -  17:05
Hall B

Personalized Medicine and Digital Health: Lessons Learned and Challenges Ahead

Co-chairs: Yair Schindel, MD, Co-Founder & Managing Partner, aMoon Fund; Prof. Varda Shalev, MD, MPA, Managing Director, Morris Kahn & Maccabi Research and Innovation Institute at Maccabi Health Care Services

11:20-11:40 Fireside Chat – The Future Doctor, Patient and In-between
Prof. Varda Shalev, MD, MPA
, Managing Director, Morris Kahn & Maccabi Research and Innovation Institute at Maccabi Health Care Services
Yair Schindel, MD, Co-Founder & Managing Partner, aMoon Fund

11:40-11:55 Noah Klein, Director of Corporate Strategy & Business Development, Nuvo Group: “Reinventing Pregnancy Monitoring and Management for the 21st Century”

11:55-12:10 Erez Gavish, Co-Founder/CEO, 2breathe Technologies Ltd: “Can Digital Therapeutics Lower Sympathetic Overactivity?”

12:10-12:30 Michal Rozen-Zvi, Director, Healthcare Informatics, IBM Research: “Learn from Screening Data and Assessing Breast Cancer Risk”

12:30-12:45 Daniella Gilboa, AIVF: “Transforming IVF with the Power of Artificial Intelligence”

12:45-13:05 Prof. Eitan Friedman, MD, PhD, Director & Founder of The Suzanne Levy-Gertner Oncogenetics Unit, Sheba Medical Center

13:05-13:20 Lihi Segal, DayTwo: “Personalized Nutrition Recommendations for Normalizing Blood Glucose Levels Based on Microbiome, Medical and Personal Records”

13:20-14:50 Lunch Break

14:50-15:05 Alex Melamud, CEO, Melcap Systems: “First Digital Health Affordable System for the Treatment of Overweight and Obesity for Billions”

15:05-15:25 Elliot Menschik, MD, PhD, Global Head, Healthcare + Life Science Startups, Amazon Web Services

15:25-15:40 Vince Gao, PhD, Founder & CEO, Govita Tech: “Association of Genetic and Metabolic Data Derived from Metabolic Pathways for Personalized Intervention of Chronic Diseases”

15:40-15:55 Seth Saltpeter, CTO, Curesponse: “A Next Generation Platform for Definitive Treatment Answers in Personalized Cancer Medicine”

15:55-16:15 Uma Makhija, Business Development Lead, Digital Health, Otsuka Pharmaceuticals: “Pharma and Digital Therapeutics Partnerships – Opportunities and Challenges”

16:15-16:30 Simona Di-Capua, Teva: “3D Printing – A Novel Approach to Design and Manufacture Personalized Medicines”

16:30-16:45 Company TBA

16:45-17:05 Wade Ackerman, Partner, FDA Regulatory group, Co-Lead of Digital Health Initiative, Covington & Burling LLP

+
11:20  -  17:30
Hall C

Cannabis’ Therapeutic Promise: Hope or Hype?

Co-chairs: Prof. Simon Benita, PhD, Head of Nano Delivery Systems, Hebrew University of Jerusalem; Ayelet Torem, Adv, Partner, Hi-Tech & Venture Capital and Head of Global Markets, Amit, Pollak, Matalon & Co

11:20-11:45 Dorman Followwill, Senior Partner, Frost & Sullivan: “Outlook for Cannabis as Therapeutic Agent”

11:45-12:05 Prof. Hinanit Koltai, PhD, Agricultural Research Organization (ARO), Volcani Center: “Medical Cannabis: from Weed to Molecules to Drug Development”

12:05-12:25 Prof. Simon Benita, PhD, Head of Nano Delivery Systems, Hebrew University of Jerusalem: “Improvement of CBD and THC Oral Bioavailability using Nano Delivery Systems”

12:25-12:45 Yossi Tam, The Hebrew University of Jerusalem: “Cannabinoid-Based Therapies: Lessons Learned from the Endocannabinoid System”

12:45-13:10 Prof. Raphael Mechoulam, PhD, Hebrew University of Jerusalem: “Cannabinoids: A Look Back and Ahead”

13:20:-14:50 Lunch Break

14:50-15:20 Prof. Itamar Raz, MD, Head, The Israeli National Diabetes Council: “Medical Cannabis treatment of Pain and Glycemic Control”

15:20-15:40 Medy Wiener, Chief Medical Officer, BOL Pharma: “Drug/Cannabinoid Clinical Development Route – Same but Different”

15:40-15:55 Company TBC

15:55-16:10 Tamir Gedo, CEO, BOL Pharma: “The Winners and Losers of the Global Cannabis Industry”

16:10-16:25 Ascher Shmulewitz, CEO, Therapix Biosciences Ltd: “Therapix Biosciences Developing Cannabinoids of the Future”

16:25-16:40 Perry Davidson, CEO, Syqe Medical Ltd

16:40-16:55 Dadi Segal, CEO, Panaxia Pharmaceutical Industries Ltd: “Panaxia – Manufacturing of Pharmaceutical Cannabis Products”

16:55-17:10 Taher Nassar, VP, Research, Bionanosim Ltd: “Bionanosim Ltd-Innovative Nano-Carriers for Improved Cannabis-BNS”

17:10-17:30 Ayelet Torem, Adv., Partner, Hi-Tech & Venture Capital and Head of Global Markets, Amit, Pollak, Matalon & Co: “Medical Cannabis Regulatory Overview”